No Risks Seen With Early Childhood Exposure to Aluminum-Adsorbed Vaccines
TUESDAY, July 15, 2025 -- Early childhood exposure to aluminum-adsorbed vaccines is not associated with an increased risk for autoimmune, atopic or allergic, or neurodevelopmental disorders, according to a study published online July 15 in the Annals of Internal Medicine.
Niklas Worm Andersson, M.D., Ph.D., from Statens Serum Institut in Copenhagen, Denmark, and colleagues examined the association between cumulative aluminum exposure from early childhood vaccination and the risk for autoimmune, atopic or allergic, and neurodevelopmental disorders in Denmark from 1997 to 2020. Participants included 1,224,176 children born in Denmark between 1997 and 2018 who were alive and resided in the country at age 2 years.
The researchers observed no association for cumulative aluminum exposure from vaccination during the first two years of life with increased rates of any of the 50 chronic disorders assessed. Per 1-mg increase in aluminum exposure, adjusted hazard ratios were 0.98 (95 percent confidence interval, 0.94 to 1.02) for any autoimmune disorder, 0.99 (95 percent confidence interval, 0.98 to 1.01) for any atopic or allergic disorder, and 0.93 (95 percent confidence interval, 0.90 to 0.97) for any neurodevelopmental disorder. The upper bounds of the 95 percent confidence intervals were incompatible with relative increases greater than 10 or 30 percent for most individually analyzed outcomes.
"Findings were incompatible with moderate-to-large relative increases in the risks for autoimmune, atopic or allergic, and neurodevelopmental disorders associated with early childhood exposure to aluminum-adsorbed vaccines for most outcomes, although small relative increases could not be statistically excluded, particularly for some rarer outcomes," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Cancer Survival Lower in Rural Areas
WEDNESDAY, Oct. 1, 2025 -- Five-year cancer survival rates for each stage of cancer (localized, regional, and distant) is lower in nonmetropolitan areas for Black and White...
Loss of Smell May Linger After COVID-19
WEDNESDAY, Oct. 1, 2025 -- Self-reported change or loss in smell or taste is an accurate signal of verified hyposmia after COVID-19, although there is also a high rate of hyposmia...
Elderly Patients Benefit From Screening Mammography
WEDNESDAY, Oct. 1, 2025 -- Patients with breast cancer diagnosed at 80 years of age or older who received screening mammography present with earlier-stage disease and have better...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.